Latecomer Merck Serono submits Rebif in Europe for early signs of MS
This article was originally published in Scrip
Executive Summary
Merck Serono has applied to the EMA for a label extension for its multiple sclerosis (MS) treatment Rebif (interferon beta-1a) to include treatment of patients with early signs of the disease.